文献速递临床免疫质量管理与危急值

商业抗SARS-CoV-2免疫测定在血清和血浆样本中的检测性能比较

Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples.
PubMed 文献 · Clin Chim Acta · 2020-07-09

该研究评估了Roche、Euroimmun和Epitope三种抗SARS-CoV-2 IgG免疫测定在血清和血浆中的诊断性能。结果显示Roche和Euroimmun特异性高于Epitope且敏感性无明显下降,血浆与血清检测一致性因测定而异,提示需按样本类型确定cut-off并建立质量标准。

要点

  • Roche和Euroimmun特异性高于Epitope,敏感性无明显下降。
  • 血浆与血清检测一致性因测定而异,需按样本类型确定cut-off。
  • 亟需SARS-CoV-2血清学检测的标准化和质量标准。

核心结论

  • Euroimmun和Roche免疫测定特异性高于Epitope且诊断敏感性无明显下降。
  • 血浆与血清检测的显著差异提示需按样本类型确定适当cut-off。
  • 亟需检测标准化和建立COVID-19血清学检测的质量标准。

研究设计与样本

  • 研究分析了51份血清样本,来自26例确诊SARS-CoV-2感染且隔离期结束后的患者和25例对照患者。
  • 使用Roche、Euroimmun和Epitope的抗SARS-CoV-2 IgG免疫测定评估诊断敏感性和特异性。
  • 纳入20对匹配的血清和血浆样本分析不同样本类型间的可比性。

主要发现

  • Roche、Euroimmun和Epitope免疫测定的诊断敏感性分别为92.3%、96.2-100%和100%。
  • Roche、Euroimmun和Epitope免疫测定的诊断特异性分别为100%、100%和84-86%。
  • 总体84-96%的样本被正确分类为阴性,92.3-95.2%被正确分类为阳性。
  • 血浆与血清检测的一致性因测定而异:Epitope r2=0.97;Euroimmun r2=0.91;Roche r2=0.76。

关键数值与推荐

  • Roche免疫测定诊断敏感性92.3%、特异性100%。
  • Euroimmun免疫测定诊断敏感性96.2-100%、特异性100%。
  • Epitope免疫测定诊断敏感性100%、特异性84-86%。
  • 血浆与血清一致性:Epitope r2=0.97;Euroimmun r2=0.91;Roche r2=0.76。

临床怎么用

  • 选择特异性较高的Roche或Euroimmun免疫测定用于抗SARS-CoV-2 IgG检测。
  • 根据样本类型(血清或血浆)确定适当的cut-off值。
  • 推动检测标准化和质量标准建立以确保COVID-19血清学检测的适当使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For epidemiologic, social and economic reasons, assessment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection prevalence and immunity are important to adapt decisions to current demands. Hence, immunoassays for detection of anti-SARS-CoV-2 antibodies are introduced rapidly without requiring FDA emergency use authorization approval. Thus, evaluation of test performance predominantly relies on laboratories. This study aimed to evaluate the test performance of recently launched commercial immunoassays in serum and plasma samples. METHODS: 51 serum samples from 26 patients with confirmed SARS-CoV-2 infection after end of quarantine and 25 control patients were analyzed using anti-SARS-CoV-2 IgG immunoassays from Roche, Euroimmun and Epitope to assess diagnostic sensitivity and specificity. 20 matching pairs of serum and plasma samples were included to analyze comparability between different specimens. RESULTS: Overall, a diagnostic sensitivity of 92.3%, 96.2-100% and 100% with a respective diagnostic specificity of 100%, 100% and 84-86% for the immunoassays from Roche, Euroimmun and Epitope were determined. In total, 84-96% of samples were correctly classified as negative and 92.3-95.2% as positive. The level of concordance between plasma- and serum-based testing diverged between the assays (Epitope r2 = 0.97; Euroimmun r2 = 0.91; Roche r2 = 0.76). CONCLUSIONS: The immunoassays from Euroimmun and Roche revealed a higher specificity than the Epitope assay without a substantial drop of diagnostic sensitivity. Significant differences between plasma- and serum-based testing highlights the need for determination of appropriate cut-offs per specimen type. Hence, there is an urgent need for test harmonization and establishment of quality standards for an appropriate use of COVID-19 serological tests.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Haselmann V, Kittel M, Gerhards C, et al. Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples. Clin Chim Acta. 2020. PMID: 32652161. doi:10.1016/j.cca.2020.07.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。